Leukaemia & Lymphoma Research scientist Dr Andrew Chantry from the University of Sheffield has been awarded the “Research Medal Award for Haematology 2010” by the Royal College of Pathologists.
This prestigious award is made annually to recognise a young specialist doctor who is carrying out outstanding research that is advancing treatments and diagnosis for patients affected by blood cancers and other blood disorders.
The Royal College of Pathologists, who oversee the professional development of haematologists, award this accolade to practicing doctors who are also training in research.
Dr Chantry received a Clinician Scientist Fellowship from Leukaemia & Lymphoma Research in 2008 allowing him to continue practicing at the local Royal Hallamshire Hospital, treating patients with myeloma, as well as pursue research at the University of Sheffield into new treatments for this blood cancer.
Dr Chantry said, “
To be nominated for the award, applicants must submit new findings from a current research project. Dr Chantry’s research focuses on treating and preventing the symptoms of bone disease, one of the most devastating side effects of myeloma.
Myeloma bone disease occurs when the processes responsible for rejuvenating bone tissue malfunction, resulting in bone lesions that can cause serious pain and disability.
Dr Chantry’s laboratory research, published in the Journal of Bone and Mineral Research in November 2010, discovered that a drug called ActRIIA.muFc can stimulate bone formation and is an effective treatment for myeloma-related bone disease. The drug also seems to suppress bone destruction and increases survival for this blood cancer, which remains incurable.
Dr Chantry adds, “Winning such an important award like this has really motivated me to continue research alongside my commitment to treating patients with myeloma. I’m inspired to take on the big challenge and work towards a final cure for myeloma, and other blood cancers.”
The award will be presented at a ceremony in April 2011, during which Dr Chantry will also be inducted as a Fellow of the Royal College of Pathologists.
Dr David Grant, Scientific Director of Leukaemia & Lymphoma Research said, “Not only does this award reflect the high calibre of research we are funding into all the blood cancers, but it also demonstrates our commitment to nurturing leaders in the field of haematology. By investing in the most promising young researchers we ensure blood cancer patients today and in the future are given the very best chance of survival. ”